Epstein-Barr Virus LMP1-Mediated Oncogenicity

Wang, Liang Wei; Jiang, Sizun; Gewurz, Benjamin E.

doi:10.1128/jvi.01718-16

Cited by 123 publications

(109 citation statements)

References 85 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…LMP1, as an EBV-encoded viral antigen, is a kind of oncogenic gene and participates in the activation of signaling pathways such as NF-κB, JNK-p38/SAPK, Ras-MAPK, PI3k-Akt and JAK-STAT, which can promote the occurrence of EMT and make nasopharyngeal carcinoma has a higher invasion and metastasis ability, which is considered to be an important factor in the development of nasopharyngeal carcinoma [42]. Studies have found that EBV-miR-BART9, EBV-miR-BART16 and EBV-miR-BART17-5p can both target the 3'UTR of LMP1 mRNA and negatively regulate the expression of LMP1.…”

Section: Antigen Expressionmentioning

confidence: 99%

Epstein barr virus encodes miRNAs to assist host immune escape

Yang

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Epstein-barr virus (EBV) is a definite tumorigenic virus, which can form lifelong latency in the host, which is difficult to be recognized and completely eliminated by the immune system. It is closely related to the occurrence and development of nasopharyngeal cancer, gastric cancer and various types of lymphoma. At present, a total of 44 Epstein-barr virus-encoded microRNAs (EBV miRNAs) have been found. In response to the immune system of the body, EBV miRNAs can inhibit the expression and presentation of viral antigens, inhibit immune activation and immunotoxicity, assisting host cells to escape from immunity, and providing conditions for further immortalized tumorigenesis of the host cells.

show abstract

Section: Antigen Expressionmentioning

confidence: 99%

Epstein barr virus encodes miRNAs to assist host immune escape

Yang

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…The EBV latent membrane protein 1 (LMP1) is a latent oncogenic protein encoded by EBV. Studies show that LMP1 harbors the oncogenic potential through NF‐κB signaling pathway and contributes to the viral life cycle in differentiating epithelia …”

Section: Introductionmentioning

confidence: 99%

Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein‐Barr virus associated nasopharyngeal carcinoma

et al. 2019

View full text Add to dashboard Cite

Exosomes have emerged as novel vehicles for proteins and other contents in cancer progression. Cyclophilin A (CYPA) is a pivotal member of immunophilin family. Whether CYPA can be detected in sera of nasopharyngeal carcinoma (NPC) patients remains to be explored. Epstein‐Barr virus (EBV) is the first identified human tumor virus and is a causative agent of NPC. The antibody of EBV capsid antigen immunoglobulin A (EBV‐VCA‐IgA) is a known biomarker of NPC, with a proportion of no more than 70% being detected positively. Hence, novel biomarkers need to be discovered for early diagnosis, prognosis, and monitoring of EBV‐associated NPC. A total of 110 NPC and 36 normal control serum samples were collected. Exosomes from these samples were extracted. The mRNA and protein expression levels of the above samples were validated by reverse transcription –quantitative polymerase chain reaction, Western blotting, or enzyme‐linked immunosorbent assay (ELISA). Finally, the results demonstrated that both the serum and exosomal CYPA levels of NPC patients were significantly higher than that of normal cases. In addition, exosomal CYPA had a much higher level than that in the whole sera. The positive rate of EBV‐VCA‐IgA antibody was 68.2% in NPC sera, and noticeably, among the cases with EBV‐VCA‐IgA negative, 80% of them presented high levels of CYPA above the standard (cutoff value). In particular, CYPA in exosomes was uniformly with higher significance than that in whole sera. Combined analysis of CYPA protein and EBV‐VCA‐IgA antibody showed a greatly higher discriminatory ability in diagnosis of NPC. Moreover, exosomal CYPA level had a positive correlation with that of the EBV‐encoded latent membrane protein 1 (LMP1) in exosomes. EBV‐positive cancer cells secreted significantly higher levels of exosomal CYPA. This study established the utility of circulating exosomal CYPA as a potential noninvasive diagnostic biomarker for EBV‐associated NPC.

show abstract

“…MiR-BART15 is capable of targeting nucleotide-bound oligomerization domain-like receptor family pyridine domaincontaining 3 (NLRP3) with less in ammation to limit in ammation and promote EBV infection [18]. LMP1 is a transmembrane latent protein encoded by EBV, which is essential for cell proliferation and transformation [19], but overexpression of LMP1 will inhibite cell proliferation, and increase the sensitivity of cells to pro-apoptotic stress [20]. According to previous reports, miR-BART19-5p can inhibit the expression of LMP1, thereby maintaining a balance between the growth-promoting effect of LMP1 and its pro-apoptotic function [10].…”

Section: Discussionmentioning

confidence: 99%

Plasma EBV miRNA Profiles Reveal Potential Biomarkers for Clinical Prognosis of Acquired Immunodeficiency Syndrome-related Lymphoma

Chen

Peng

Guo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Acquired Immunodeficiency Syndrome-related lymphoma (ARL) is closely related to Epstein-Barr virus (EBV) infection. However, there are few studies on the occurrence and development of EBV miRNAs in ARL patients.Methods The plasma of 5 EBV-infected ARL patients and 8 EBV-infected HIV patients were screened for EBV miRNAs differentially expressed between the two groups through EBV microRNA quantification chip. The plasma of 35 EBV-infected ARL patients and 20 EBV-infected HIV patients was verified by qRT-PCR expanded samples. And we gave a further analysis of the correlation between differentially expressed EBV miRNAs and clinical prognosis indicators in ARL patients.Results 1. There were differential expressions of EBV miRNAs in the plasma of EBV-infected ARL patients and EBV-infected HIV patients. It was found that EBV-miR-BART2-5p,EBV-miR-BART8-3p,EBV-miR-BART15, EBV-miR-BART19-5p expression was significantly up-regulated and EBV-miR-BART9-5p expression was significantly down-regulated; 2. EBV microRNAs with significantly different expressions in the screening results were expanded and verified by qRT-PCR, and the differential expression was found to be consistent with the screening results; 3. The relative expression levels of EBV-miR-BART8-3p in plasma were positive correlated with the International Prognostic Index (IPI) score of Lymphoma(r = 0.37,P = 0.03),EBV-miR-BART19-5p was positive correlated with B symptoms (r = 0.42,P = 0.01) and EBV-miR-BART9-5p, was positive correlated with Eastern Cooperative Oncology Group (ECOG) scores (r = 0.35,P = 0.04).Conclusions The expression of EBV-miR-BART2-5p, EBV-miR-BART8-3p, EBV-miR-BART15,EBV-miR-BART19-5p,EBV-miR-BART9-5p in ARL patients were highly different; and EBV-miR-BART8-3p, EBV-miR-BART19-5p, EBV-miR-BART9-5p could be used as the biomarkers for the prognosis of ARL.

show abstract

Epstein-Barr Virus LMP1-Mediated Oncogenicity

Cited by 123 publications

References 85 publications

Epstein barr virus encodes miRNAs to assist host immune escape

Epstein barr virus encodes miRNAs to assist host immune escape

Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein‐Barr virus associated nasopharyngeal carcinoma

Plasma EBV miRNA Profiles Reveal Potential Biomarkers for Clinical Prognosis of Acquired Immunodeficiency Syndrome-related Lymphoma

Contact Info

Product

Resources

About